Baird Reiterates Neutral Rating on Amgen (AMGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts AMGN Hot Sheet
Rating Summary:
18 Buy, 20 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Baird analyst Brian Skorney reiterated a Neutral rating and $173.00 price target on Amgen (NASDAQ: AMGN)
The analyst comments "Amgen's updated KRAS lung cancer data continue to look good, although compared to the super-high expectations set by the ASCO data, there is likely some letdown as response rates look modestly worse and durability wasn't fantastic. However, it's rare to see anything like a single-agent ORR of around 50% in a relapsed lung cancer setting."
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $199.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) PT Raised to $400 at Bernstein SocGen Group
- SharkNinja (SN) PT Raised to $300 at Jefferies
- Amgen (AMGN) PT Raised to $410 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
